231 related articles for article (PubMed ID: 25544127)
21. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
Watanabe G; Behrns KE; Kim JS; Kim RD
Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
[TBL] [Abstract][Full Text] [Related]
22. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.
Hao B; Zheng N; Schulman BA; Wu G; Miller JJ; Pagano M; Pavletich NP
Mol Cell; 2005 Oct; 20(1):9-19. PubMed ID: 16209941
[TBL] [Abstract][Full Text] [Related]
23. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
24. RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.
Alfano L; Guida T; Provitera L; Vecchio G; Billaud M; Santoro M; Carlomagno F
J Clin Endocrinol Metab; 2010 Jul; 95(7):3552-7. PubMed ID: 20444924
[TBL] [Abstract][Full Text] [Related]
25. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells.
Cheung CH; Chen HH; Cheng LT; Lyu KW; Kanwar JR; Chang JY
Mol Cancer; 2010 Apr; 9():77. PubMed ID: 20398291
[TBL] [Abstract][Full Text] [Related]
26. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
[TBL] [Abstract][Full Text] [Related]
27. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
28. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest.
Bedin M; Gaben AM; Saucier C; Mester J
Int J Cancer; 2004 May; 109(5):643-52. PubMed ID: 14999769
[TBL] [Abstract][Full Text] [Related]
29. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Bonvini P; Dalla Rosa H; Vignes N; Rosolen A
Cancer Res; 2004 May; 64(9):3256-64. PubMed ID: 15126367
[TBL] [Abstract][Full Text] [Related]
30. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
31. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines.
García-Morales P; Carrasco-García E; Ruiz-Rico P; Martínez-Mira R; Menéndez-Gutiérrez MP; Ferragut JA; Saceda M; Martínez-Lacaci I
Oncogene; 2007 Nov; 26(51):7185-93. PubMed ID: 17525741
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
Okamoto J; Mikami I; Tominaga Y; Kuchenbecker KM; Lin YC; Bravo DT; Clement G; Yagui-Beltran A; Ray MR; Koizumi K; He B; Jablons DM
J Thorac Oncol; 2008 Oct; 3(10):1089-95. PubMed ID: 18827603
[TBL] [Abstract][Full Text] [Related]
34. Cks1 promotion of S phase entry and proliferation is independent of p27Kip1 suppression.
Hoellein A; Graf S; Bassermann F; Schoeffmann S; Platz U; Hölzlwimmer G; Kröger M; Peschel C; Oostendorp R; Quintanilla-Fend L; Keller U
Mol Cell Biol; 2012 Jul; 32(13):2416-27. PubMed ID: 22508990
[TBL] [Abstract][Full Text] [Related]
35. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.
Wu WC; Wu MH; Chang YC; Hsieh MC; Wu HJ; Cheng KC; Lai YH; Kao YH
Exp Eye Res; 2010 Aug; 91(2):211-9. PubMed ID: 20493187
[TBL] [Abstract][Full Text] [Related]
36. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
37. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
38. Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors.
Tomiatti V; Istvánffy R; Pietschmann E; Kratzat S; Hoellein A; Quintanilla-Fend L; von Bubnoff N; Peschel C; Oostendorp RA; Keller U
Oncogene; 2015 Aug; 34(33):4347-57. PubMed ID: 25417705
[TBL] [Abstract][Full Text] [Related]
39. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
40. Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK).
Qing G; Yan P; Xiao G
Cell Res; 2006 Nov; 16(11):895-901. PubMed ID: 17088896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
